NCT00692354已完成1 期
A Phase I Study to Evaluate the Safety and Tolerability, of the Aminopeptidase Inhibitor, CHR-2797, in Patients With Advanced Tumours
Chroma Therapeutics0 个研究点目标入组 41 人开始时间: 2004年10月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 41
- 主要终点
- To determine the safety, tolerability, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CHR-2797 when administered orally, once daily, to patients with advanced solid tumours.
研究概览
简要总结
The primary objective of this study was to determine the safety, tolerability, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CHR-2797 when administered orally, once daily, to patients with advanced solid tumours.
The secondary objectives of this study were:
- To determine pharmacokinetic parameters for CHR-2797 when administered orally at increasing dose levels;
- To investigate the pharmacodynamic effects of CHR-2797 in blood mononuclear cells and, when possible, tumour cells; - To enable a preliminary assessment of anti-tumour activity of CHR-2797.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed, informed consent
- •Histological or cytologically confirmed malignant solid tumour refractory to standard therapy or for which no standard therapy exists
- •Evaluable disease
- •Recovered from the acute adverse effects of prior therapies (excluding alopecia and grade 1 neuropathy)
- •Adequate bone marrow, hepatic and renal function including the following:
- •Hb ≥ 9.0 g/dl, absolute neutrophil count ≥ 1.5 x 109/L, platelets ≥ 100x109/L
- •Total bilirubin ≤ 1.5 x upper normal limit
- •AST and ALT ≤ 2.5 x upper normal limit (or ≤ 5 x UNL in the presence of liver metastases)
- •Creatinine ≤1.5 x upper normal limit
- •Age < 18 years
- •Performance status (PS) < 2 (ECOG scale)
- •Estimated life expectancy greater than 3 months
- •Female patients with reproductive potential had to have a negative serum pregnancy test within 7 days of treatment. Both women and men had to agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months after discontinuation of treatment. Acceptable methods of contraception included IUD, oral contraceptive, sub-dermal implant and double barrier (condom with a contraceptive sponge or contraceptive pessary)
排除标准
- •Anti-cancer therapy including chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other investigational agents within the 4 weeks prior to study entry (or a longer period depending on the defined characteristics of the agents used e.g. 6 weeks for mitomycin or nitrosourea). In patients with progressive disease (PD), continuation of LHRH agonists for prostate cancer, bisphosphonates for bone disease and corticosteroids was permitted provided the dose was stable before and during the study
- •Co-existing active infection or serious concurrent illness
- •Significant cardiovascular disease as defined by
- •History of congestive heart failure requiring therapy
- •History of unstable angina pectoris or myocardial infarction up to 6 months prior to study entry
- •Presence of severe valvular heart disease
- •Presence of a ventricular arrhythmia requiring treatment
- •Any co-existing medical condition that in the Investigator's judgement substantially increased the risk associated with the patient's participation in the study
- •Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies
- •Gastrointestinal disorders that might have interfered with absorption of the study drug
- •Persistent grade 2 or greater toxicities from any cause
- •Patients with known brain tumours or metastases should have been excluded from this clinical study because of their poor prognosis and because they often develop progressive neurologic dysfunction that would have confounded the evaluation of neurologic and other AEs
- •Pregnant or breast-feeding women
结局指标
主要结局
To determine the safety, tolerability, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CHR-2797 when administered orally, once daily, to patients with advanced solid tumours.
时间窗: 3 years
次要结局
- To determine the PK parameters for oral CHR-2797 at increasing dose levels;(3 years)
- To investigate the PD effects of CHR-2797 in blood and tumour cells(3 years)
- To enable a preliminary assessment of anti-tumour activity of CHR-2797(3 years)
研究者
相似试验
已完成
1 期
Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard TherapySolid TumorsNCT02499224CellabMED39
招募中
1 期
A Phase I Study of HS-10386 in Participants With Advanced Solid TumorsAdvanced Solid TumorNCT05911464Jiangsu Hansoh Pharmaceutical Co., Ltd.248
已完成
1 期
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy SubjectsHealthy VolunteersPharmacokinetics of ASP7962NCT02136316Astellas Pharma Europe B.V.48
已完成
1 期
Phase I Trial of Tanibirumab in Advanced or Metastatic CancerAdvanced CancerMetastatic CancerNCT01660360PharmAbcine26
终止
1 期
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) TreatmentMelanomaNCT03978611Bristol-Myers Squibb11